Serina Therapeutics, Inc. (“Serina”) (NYSE American: SER), a clinical-stage biotechnology company developing its proprietary POZ Platform ™ drug delivery technology, announced that Serina Therapeutics ...

In September 2007, the EMEA organized a workshop on immunogenicity assessment, giving various stakeholders the opportunity to comment and critically discuss the European draft guideline 3.

Novavax NVAX announced that it has started dosing participants in the phase III study evaluating its experimental ...

EpiVax, Inc., a leader in preclinical immunogenicity risk assessment for biologic and peptide therapeutics, celebrates a ...

Immunogenicity was assessed by hemagglutination-inhibition (HI) prevaccination and 28 days after each vaccination. Immunogenic non-inferiority QIV versus TIV for shared strains, and superiority ...

Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its Matrix-M™ adjuvant, today announced ...

So, what is the adjuvant element that stimulates immunogenicity and makes these vaccines successful? Ishii and colleagues now reveal that TBK1 (TANK-binding kinase 1) mediates the adjuvant effect ...

Enhance Toxicity Assessments with Human-Relevant Data Discover how advanced ex vivo human skin models are reshaping toxicity ...

The concomitant administration of multiple vaccines at a single clinic visit reduces the number of required visits to healthcare providers and can improve compliance with vaccine recommendations ...

Novavax (NVAX) announced that the first participants have been dosed in its COVID-19-Influenza Combination and stand-alone seasonal influenza ...